Drug transport in blood: Lipoproteins as transporters of psychotropic drugs (group contribution)
Journal article (drug transport)
Pharmacology · Nanomedicine · AML
Pharmacology & Nanomedicine
University of Bergen (UiB)Welcome to our lab
Lars Herfindal — Pharmacology & Nanomedicine (concept)
Our work translates intracellular-signalling insight into nanoparticle-enabled therapies for acute myeloid leukaemia. We combine mechanistic cell biology with formulation science and preclinical testing.
Principal investigator
Lars Herfindal
Professor in Pharmacology
Professor in Pharmacology at the University of Bergen. Research includes intracellular signalling, nanocarrier development and natural-product discovery with a translational focus on AML.
Full profile →Programmes
Four focus programmes
01
p53 and the DNA-damage response in acute myeloid leukaemia
Mechanistic study of how functional p53 controls acute responses to anthracycline chemotherapy and shapes recovery and resistance in AML models.
02
Liposomal co‑formulations to overcome anthracycline resistance
Design and preclinical testing of multifunctional liposomes co‑encapsulating anthracyclines with resistance-modifying agents to enhance AML cytotoxicity and selectivity.
03
Nanocarrier strategies and drug repurposing for AML
Exploration of nanoparticle delivery to improve delivery of repurposed agents and novel payloads for AML therapy, with emphasis on translational obstacles and formulation strategies.
04
Bioprospecting and natural-product leads for anti‑leukaemic agents
Screening and mechanistic follow-up of bioactive compounds from marine microorganisms and plants to identify novel modulators of apoptosis, cell‑cycle and kinase signalling relevant to AML.
Selected publications
Recent and defining work
2013↗2014↗2016↗2019↗2020
Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen
BMC Cancer (PMC)
Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia
European Journal of Pharmaceutics and Biopharmaceutics
The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status
Review (nanocarriers/AML)
Selected thesis and project reports on nanocarriers, zebrafish models and drug biotransformation (group outputs)
Various (project reports & theses)
↗
Join the group